Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

ImmunityBio Q2 EPS $(0.10) Beats $(0.11) Estimate, Sales $26.425M Beat $21.488M Estimate

Author: Benzinga Newsdesk | August 05, 2025 06:41am
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 50 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $26.425 million which beat the analyst consensus estimate of $21.488 million by 22.98 percent. This is a 2.42K percent increase over sales of $1.047 million the same period last year.

Posted In: IBRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist